Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824064 · ClinicalTrials.gov registry record · Phase 2
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Riboscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT06824064 is a Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer that is actively recruiting participants, run by Riboscience. The registered enrollment target is 150 participants, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06824064, a Phase 2 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, is actively recruiting participants, sponsored by Riboscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RBS2418
Study Locations (3)
Texas
- Community Clinical Trials - Kingwood
Ho Chi Minh City
- Tam Anh TP. Ho Chi Minh General Hospital - Ho Chi Minh City
Other
- Tam Anh, Ha Noi General Hospital - Hà Nội
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824064
The ClinicalTrials.gov registry entry for NCT06824064 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (18% lower). The listed sponsor is Riboscience, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06824064 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Texas, Ho Chi Minh City, Other.
Frequently Asked Questions
What is clinical trial NCT06824064 about?
NCT06824064 is a clinical study titled "Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer". RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and lead...
What is the current status of trial NCT06824064?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-01-17. Estimated completion is 2027-12.
What conditions does trial NCT06824064 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer.
What interventions are being tested in trial NCT06824064?
The interventions under investigation include: Placebo (DRUG), RBS2418 (DRUG).
Who is sponsoring clinical trial NCT06824064?
This trial is sponsored by Riboscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824064 being conducted?
This trial has 3 study locations across Texas, Ho Chi Minh City. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.